Evidence map›Paper›PMID 32696266›Full record

ArticleBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2020

Retention Rate and Efficacy of the Biosimilar CT-P13 Versus Reference Infliximab in Patients with Ankylosing Spondylitis: A Propensity Score-Matched Analysis from the Korean College of Rheumatology Biologics Registry.

Hyoun-Ah Kim, Eunyoung Lee, Sun-Kyung Lee, Yong-Beom Park, Kichul Shin

Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01965132 (Korean College of Rheumatology Biologics and Targeted Therapy Registry), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01965132 recruitingnot on this map

Korean College of Rheumatology Biologics and Targeted Therapy Registry

Typeobservational_patient_registrySponsorSeoul National University HospitalRan2012 to 2030Enrolled10,000ConditionsRheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic ArthritisArmsBiologic or targeted synthetic DMARD
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Hyoun-Ah KimDepartment of Rheumatology, Ajou University School of Medicine, Suwon, Republic of Korea.ORCID http://orcid.org/0000-0003-2609-3367
Eunyoung LeeDepartment of Biomedical Informatics, Ajou University School of Medicine, Suwon, Republic of Korea.
Sun-Kyung LeeDivision of Rheumatology, Seoul Metropolitan Government-Seoul National University Hospital Boramae Medical Center, Seoul, Republic of Korea.
Yong-Beom ParkDepartment of Internal Medicine (Division of Rheumatology), Yonsei University College of Medicine, Severance Hospital, Seoul, Republic of Korea.
Kichul ShinDivision of Rheumatology, Seoul Metropolitan Government-Seoul National University Hospital Boramae Medical Center, Seoul, Republic of Korea. kideb1@gmail.com.ORCID http://orcid.org/0000-0002-6749-7598
Ajou University · KRSeoul Metropolitan Government · KRYonsei University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLong-term, real-world data are required to support the use of CT-P13 in chronic conditions such as ankylosing spondylitis. However, real-world evidence may be influenced by selection bias, which can confound outcomes. The aim of the current analysis was to confirm the long-term comparability of CT-P13 and reference infliximab treatment in patients with ankylosing spondylitis, using propensity score matching to adjust for baseline differences between groups.

methodsA propensity score-matching analysis was conducted on data from patients with ankylosing spondylitis in the Korean College of Rheumatology Biologics registry who received CT-P13 or reference infliximab. Drug retention, reasons for biologic therapy changes or discontinuation, and efficacy parameters were analyzed overall and by treatment line with up to 4 years of follow-up. Adverse events were recorded for each treatment group.

resultsPropensity score matching was effective in matching 124 CT-P13-treated and 124 reference infliximab-treated patients. Median treatment duration and drug retention were similar between CT-P13 and reference infliximab. Three-year retention rates (95% confidence interval [CI]) were 64.2% (53.5-73.0) for CT-P13 and 55.6% (42.9-66.6) for reference infliximab. Overall, 17.1% (CT-P13) and 29.3% (reference infliximab) of patients discontinued biologic therapy, and 20.0% (CT-P13) and 15.2% (reference infliximab) changed biologic therapy. Efficacy assessments were generally similar between groups; both treatments were well tolerated.

conclusionsPropensity score-matching analysis confirmed that CT-P13 treatment was not associated with significant differences in drug retention, treatment duration, most efficacy parameters, or safety versus reference infliximab in Korean patients with ankylosing spondylitis, building evidence for the long-term comparability of these treatments.

trial registrationClinicalTrials.gov identifier: NCT01965132.

Indexed as

Antirheumatic AgentsBiosimilar PharmaceuticalsRheumatologySpondylitis, AnkylosingAntibodies, MonoclonalHumansInfliximabPropensity ScoreRegistriesRepublic of KoreaTreatment OutcomeAntibodies, MonoclonalAntirheumatic AgentsBiosimilar PharmaceuticalsCT-P13Infliximab

Identifiers

PMID32696266
PMCPMC7391390
OpenAlexW3044757408

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.